October 2026 pulmonology highlights include FDA accelerated approval of Voceryq for recurrent respiratory papillomatosis and CHEST 2026 data.
News|Articles|April 8, 2025
Q1 2025 Recap: Pulmonology News and Updates
Author(s)Victoria Johnson
Fact checked by: Tim Smith
Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:
Advertisement
Advertisement
Pulmonology continues to evolve rapidly, driven by innovation in rare disease treatment, inhaled therapies, and personalized approaches to respiratory care. In the past few months, progress has extended across high-burden conditions like COPD and asthma, with new candidates showing promise where options have long been limited.
Related to this article
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In a 50-patient rhinovirus challenge study, a single nasal ETH47 dose cut peak viral load 40-fold, though the primary endpoint was not significant.
Advertisement
Advertisement